Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. / Kos, Zuzana; Roblin, Elvire; Kim, Rim S; Michiels, Stefan; Gallas, Brandon D; Chen, Weijie; van de Vijver, Koen K; Goel, Shom; Adams, Sylvia; Demaria, Sandra; Viale, Giuseppe; Nielsen, Torsten O; Badve, Sunil S; Symmans, W Fraser; Sotiriou, Christos; Rimm, David L; Hewitt, Stephen; Denkert, Carsten; Loibl, Sibylle; Luen, Stephen J; Bartlett, John M S; Savas, Peter; Pruneri, Giancarlo; Dillon, Deborah A; Cheang, Maggie Chon U; Tutt, Andrew; Hall, Jacqueline A; Kok, Marleen; Horlings, Hugo M; Madabhushi, Anant; van der Laak, Jeroen; Ciompi, Francesco; Laenkholm, Anne-Vibeke; Bellolio, Enrique; Gruosso, Tina; Fox, Stephen B; Araya, Juan Carlos; Floris, Giuseppe; Hudeček, Jan; Voorwerk, Leonie; Beck, Andrew H; Kerner, Jen; Larsimont, Denis; Declercq, Sabine; Van den Eynden, Gert; Pusztai, Lajos; Ehinger, Anna; Singh, Rajendra; Balslev, Eva; Stovgaard, Elisabeth Ida Specht; International Immuno-Oncology Biomarker Working Group.
I: npj Breast Cancer, Bind 6, 2020, s. 17.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
AU - Kos, Zuzana
AU - Roblin, Elvire
AU - Kim, Rim S
AU - Michiels, Stefan
AU - Gallas, Brandon D
AU - Chen, Weijie
AU - van de Vijver, Koen K
AU - Goel, Shom
AU - Adams, Sylvia
AU - Demaria, Sandra
AU - Viale, Giuseppe
AU - Nielsen, Torsten O
AU - Badve, Sunil S
AU - Symmans, W Fraser
AU - Sotiriou, Christos
AU - Rimm, David L
AU - Hewitt, Stephen
AU - Denkert, Carsten
AU - Loibl, Sibylle
AU - Luen, Stephen J
AU - Bartlett, John M S
AU - Savas, Peter
AU - Pruneri, Giancarlo
AU - Dillon, Deborah A
AU - Cheang, Maggie Chon U
AU - Tutt, Andrew
AU - Hall, Jacqueline A
AU - Kok, Marleen
AU - Horlings, Hugo M
AU - Madabhushi, Anant
AU - van der Laak, Jeroen
AU - Ciompi, Francesco
AU - Laenkholm, Anne-Vibeke
AU - Bellolio, Enrique
AU - Gruosso, Tina
AU - Fox, Stephen B
AU - Araya, Juan Carlos
AU - Floris, Giuseppe
AU - Hudeček, Jan
AU - Voorwerk, Leonie
AU - Beck, Andrew H
AU - Kerner, Jen
AU - Larsimont, Denis
AU - Declercq, Sabine
AU - Van den Eynden, Gert
AU - Pusztai, Lajos
AU - Ehinger, Anna
AU - Singh, Rajendra
AU - Balslev, Eva
AU - Stovgaard, Elisabeth Ida Specht
AU - International Immuno-Oncology Biomarker Working Group
N1 - © The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the clinical and research communities. We evaluated sources of variability in sTIL assessment by pathologists in three previous sTIL ring studies. We identify common challenges and evaluate impact of discrepancies on outcome estimates in early TNBC using a newly-developed prognostic tool. Discordant sTIL assessment is driven by heterogeneity in lymphocyte distribution. Additional factors include: technical slide-related issues; scoring outside the tumor boundary; tumors with minimal assessable stroma; including lymphocytes associated with other structures; and including other inflammatory cells. Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to affect treatment selection if cutpoints are employed. Scoring and averaging multiple areas, as well as use of reference images, improve consistency of sTIL evaluation. Moreover, to assist in avoiding the pitfalls identified in this analysis, we developed an educational resource available at www.tilsinbreastcancer.org/pitfalls.
AB - Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the clinical and research communities. We evaluated sources of variability in sTIL assessment by pathologists in three previous sTIL ring studies. We identify common challenges and evaluate impact of discrepancies on outcome estimates in early TNBC using a newly-developed prognostic tool. Discordant sTIL assessment is driven by heterogeneity in lymphocyte distribution. Additional factors include: technical slide-related issues; scoring outside the tumor boundary; tumors with minimal assessable stroma; including lymphocytes associated with other structures; and including other inflammatory cells. Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to affect treatment selection if cutpoints are employed. Scoring and averaging multiple areas, as well as use of reference images, improve consistency of sTIL evaluation. Moreover, to assist in avoiding the pitfalls identified in this analysis, we developed an educational resource available at www.tilsinbreastcancer.org/pitfalls.
U2 - 10.1038/s41523-020-0156-0
DO - 10.1038/s41523-020-0156-0
M3 - Journal article
C2 - 32411819
VL - 6
SP - 17
JO - npj Breast Cancer
JF - npj Breast Cancer
SN - 2374-4677
ER -
ID: 259929731